Advances in Heart Failure - Is It Time to Redefine Patient Selection for Sodium-Glucose Co-transporter 2 Inhibitors?
Published: 09 October 2020
-
Views:
61
-
Likes:
7
-
Views:
61
-
Likes:
7
-
11m 45s
-
16m 28sPart 4 Q&A Discussion
-
15m 14s
-
9m 33sPart 1 SGLT2s as a Heart Failure Drug – How Did We Get Here? Martin R Cowie, Anne Cornelissen
Overview
This educational symposium was originally broadcast as part of the ESC 2020 Digital Congress.
The programme focuses on summarising recent data on SGLT2 inhibitors showing reductions in CV risk, HF hospitalisations and mortality, as well as improved quality-of-life. The expert panel also discuss how these agents should be introduced into clinical practice and contemporary heart failure guidelines for both diabetics and non-diabetics.
Learning Objectives
- Discuss Current SGLT2 Data and Guideline Recommendations for Utilization in Heart Failure
- Evaluate Emerging Data on the Treatment of Heart Failure with SGLT2 Inhibitors
- Understand the Implications of Emerging Data on the Treatment of Heart Failure With SGLT2 Inhibitors
More from this programme
Part 1
SGLT2s as a Heart Failure Drug – How Did We Get Here?
Part 2
Emerging Data SGLT2 Inhibitors in Heart Failure
Part 3
Guidelines and Practice Implications
Part 4
Q&A Discussion
| 1 session | |
| Q&A Discussion | Watch now |
Part 5
Follow-up Peer-to Peer Discussion
| 1 session | |
| Follow-up Peer-to Peer Discussion | Watch now |
About the episode
Lorem ipsum dolor sit amet, consectetur adipiscing elit. In interdum, lorem et suscipit efficitur, nulla arcu porta libero, eget dapibus augue turpis ut tellus. Fusce efficitur vel magna consequat porttitor. Vestibulum aliquam volutpat purus. Vivamus quis ligula scelerisque, malesuada felis sit amet, posuere risus. Nullam sapien elit, rutrum vitae dignissim vitae, rutrum sit amet magna. Fusce in cursus orci, consequat placerat purus. Vestibulum rhoncus iaculis imperdiet. Donec feugiat tincidunt viverra. Nam id rhoncus arcu. Maecenas bibendum imperdiet nunc vitae faucibus. Pellentesque habitant morbi tristique senectus et netus et malesuada fames ac turpis egestas. Curabitur tellus libero, fermentum ut fermentum vel, placerat quis risus. Phasellus gravida quis neque eu ullamcorper.
- Aenean porttitor viverra justo et tristique. Orci varius natoque penatibus et magnis dis parturient montes, nascetur ridiculus mus. Nullam ipsum elit, tempor eget maximus vitae, euismod a nisl. Nam placerat, leo nec feugiat malesuada, orci felis porta lectus, sit amet cursus velit tortor vel urna. Mauris vitae tortor in purus accumsan scelerisque. Maecenas sit amet commodo tellus. Aenean sit amet magna mauris. Nam imperdiet, ante in tincidunt posuere, elit velit pharetra arcu, et ornare ante ligula at felis. Curabitur vulputate pharetra est, sed aliquam nisi pretium nec. Sed vulputate ut odio at sodales. Aenean semper sem ut nisi placerat, ac elementum augue interdum. Donec ac arcu a lectus lacinia ultrices quis sed velit. Fusce vitae blandit ligula. Sed ut quam pellentesque, mollis dui vitae, ultrices risus. Quisque in lectus porttitor, pulvinar velit eu, rutrum lacus. Sed viverra interdum dapibus.
Faculty Biographies
Faiez Zannad
Professor of Therapeutics and Cardiology, Head of CIC
Dr Faiez Zannad is Professor of Therapeutics & Cardiology and Head of the Division of Heart Failure, Hypertension and Preventive Cardiology for the department of Cardiovascular Disease of the Academic Hospital (CHU) in Nancy and the Director of the Clinical Investigation Centre (Inserm-CHU).
Dr Zannad is currently the Chairman of the ESC Working group on Pharmacology and Drug Therapy as well as a Boardmember of the ESC Heart Failure Association. He is Past-President of the French Society of Hypertension.
Dr Zannad is Co-Editor-in-Chief for Fundamental and Clinical Pharmacology, the official journal of the European Pharmacology Societies Federation (EUPHAR). He chairs and organises annual international meetings on CardioVascular Clinical Trials (CVCT) and on Biomarkers in Heart Failure.